Rifaximin SSD in Dementia Trial

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

May 31, 2026

Conditions

Dementia Alzheimer TypeDementia Associated With Cerebrovascular Disease

Interventions

DRUG

Rifaximin SSD 40 mg IR tablet

Drug therapy vs placebo

DRUG

Placebo

Placebo drug

Trial Locations (1)

RECRUITING

Richmond VA Medical Center, Richmond

All Listed Sponsors

collaborator

Bausch Health Americas, Inc.

INDUSTRY

lead

Jasmohan Bajaj

FED

NCT06718686 - Rifaximin SSD in Dementia Trial | Biotech Hunter | Biotech Hunter